Bernstein Initiates Coverage On Regeneron Pharmaceuticals with Outperform Rating, Announces Price Target of $1125
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst William Pickering initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with an Outperform rating and a price target of $1125.
March 12, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bernstein initiated coverage on Regeneron Pharmaceuticals with an Outperform rating and a price target of $1125.
The initiation of coverage by Bernstein with an Outperform rating and a high price target suggests a positive outlook on Regeneron Pharmaceuticals' stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100